Atenolol
Atenolol, Tenoretic, Tenormin (atenolol) is a small molecule pharmaceutical. Atenolol was first approved as Tenormin on 1982-01-01. It is used to treat angina pectoris, atrial fibrillation, atrial flutter, heart failure, and hypertension amongst others in the USA. The pharmaceutical is active against beta-1 adrenergic receptor. In addition, it is known to target beta-2 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Atenolol, Tenormin (discontinued: Atenolol, Tenormin)
CombinationsAtenolol chlorthalidone, Tenoretic (discontinued: Atenolol chlorthalidone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Atenolol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TENORMIN | TWi Pharmaceuticals | N-018240 RX | 1982-01-01 | 3 products, RLD, RS |
Show 1 discontinued
Atenolol
+
Chlorthalidone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TENORETIC 100 | TWi Pharmaceuticals | N-018760 RX | 1984-06-08 | 1 products, RLD, RS |
| TENORETIC 50 | TWi Pharmaceuticals | N-018760 RX | 1984-06-08 | 1 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| atenolol | ANDA | 2026-09-11 |
| atenolol and chlorthalidone | ANDA | 2026-08-27 |
| atenolol scopolamine | unapproved drug other | 2014-10-15 |
| tenormin | New Drug Application | 2025-09-18 |
Indications
FDA
EMA
Show 3 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07A: Beta blocking agents
— C07AB: Beta blocking agents, selective
— C07AB03: Atenolol
— C07AB11: S-atenolol
— C07B: Beta blocking agents and thiazides
— C07BB: Beta blocking agents, selective, and thiazides
— C07BB03: Atenolol and thiazides
— C07C: Beta blocking agents and other diuretics
— C07CB: Beta blocking agents, selective, and other diuretics
— C07CB03: Atenolol and other diuretics
— C07CB53: Atenolol and other diuretics, combinations
— C07D: Beta blocking agents, thiazides and other diuretics
— C07DB: Beta blocking agents, selective, thiazides and other diuretics
— C07DB01: Atenolol, thiazides and other diuretics
— C07F: Beta blocking agents, other combinations
— C07FB: Beta blocking agents and calcium channel blockers
— C07FB03: Atenolol and nifedipine
HCPCS
No data
Clinical
Clinical Trials
135 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 4 | 3 | 10 | 27 | 11 | 54 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 8 | 2 | 2 | 12 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 4 | 5 | 1 | 10 |
| Marfan syndrome | D008382 | Orphanet_558 | Q87.4 | — | 2 | 5 | 1 | — | 8 |
| Healthy volunteers/patients | — | — | — | 2 | 1 | — | 1 | 3 | 7 |
| Essential hypertension | D000075222 | — | I10 | — | — | 1 | 4 | 1 | 6 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | 3 | 2 | 6 |
| Infarction | D007238 | EFO_0009463 | — | — | — | 1 | 3 | 2 | 6 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | 1 | 4 | 6 |
| Angina pectoris | D000787 | EFO_0003913 | I20 | 1 | 1 | 1 | 3 | — | 6 |
Show 46 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | — | 3 | — | — | 3 |
| Neoplasms | D009369 | — | C80 | — | — | 1 | — | 1 | 2 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | — | 2 | — | — | 2 |
| Port-wine stain | D019339 | — | Q82.5 | — | — | 2 | — | — | 2 |
| Capillary hemangioma | D018324 | — | Q82.5 | — | — | 2 | — | — | 2 |
| Cerebral small vessel diseases | D059345 | — | — | — | — | 1 | — | — | 1 |
| Aortic valve disease | D000082862 | — | — | — | — | 1 | — | — | 1 |
| Bicuspid aortic valve disease | D000082882 | — | — | — | — | 1 | — | — | 1 |
| Ascending aorta dissection | D000094630 | — | — | — | — | 1 | — | — | 1 |
| Cardiomegaly | D006332 | EFO_0002503 | I51.7 | — | 1 | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tachycardia | D013610 | — | R00.0 | 1 | 1 | — | — | 2 | 3 |
| Pheochromocytoma | D010673 | — | — | — | 1 | — | — | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | — | — | 1 |
| Vestibular diseases | D015837 | EFO_0009691 | H81 | — | 1 | — | — | — | 1 |
| Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | 1 | 1 | — | — | — | 1 |
| Orthostatic intolerance | D054971 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | 2 | — | — | — | — | 2 |
| Pregnancy complications | D011248 | — | — | 1 | — | — | — | — | 1 |
| Morbid obesity | D009767 | EFO_0001074 | — | 1 | — | — | — | — | 1 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 2 | 2 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 2 | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
| Thoracic aortic aneurysm | D017545 | EFO_0004282 | — | — | — | — | — | 1 | 1 |
| Multiple endocrine neoplasia type 1 | D018761 | — | E31.21 | — | — | — | — | 1 | 1 |
| Weight loss | D015431 | — | — | — | — | — | — | 1 | 1 |
| Cachexia | D002100 | — | R64 | — | — | — | — | 1 | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 1 | 1 |
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | — | 1 | 1 |
| Orthognathic surgery | D057909 | — | — | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Atenolol |
| INN | atenolol |
| Description | Atenolol is an ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent. It has a role as a beta-adrenergic antagonist, an anti-arrhythmia drug, an antihypertensive agent, a sympatholytic agent, a xenobiotic and an environmental contaminant. It is a member of ethanolamines, a monocarboxylic acid amide and a propanolamine. |
| Classification | Small molecule |
| Drug class | beta-blockers (propranolol type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)NCC(O)COc1ccc(CC(N)=O)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 29122-68-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL24 |
| ChEBI ID | 2904 |
| PubChem CID | 2249 |
| DrugBank | DB00335 |
| UNII ID | 50VV3VW0TI (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Atenolol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Atenolol
+
Chlorthalidone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
22,811 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use